These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 16753366)

  • 41. Role of pelvic lymph node dissection in lymph node-negative patients with invasive bladder cancer.
    Shirotake S; Kikuchi E; Matsumoto K; Yazawa S; Kosaka T; Miyajima A; Nakagawa K; Oya M
    Jpn J Clin Oncol; 2010 Mar; 40(3):247-51. PubMed ID: 19887521
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A thorough pelvic lymph node dissection in presence of positive margins associated with better clinical outcomes in radical cystectomy patients.
    Canter D; Guzzo TJ; Resnick MJ; Bergey MR; Sonnad SS; Tomaszewski J; VanArsdalen K; Malkowicz SB
    Urology; 2009 Jul; 74(1):161-5. PubMed ID: 19371932
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Recurrence-free survival after radical cystectomy of patients downstaged by transurethral resection.
    Nielsen ME; Bastian PJ; Palapattu GS; Trock BJ; Schoenberg MP; Chan T; Rogers CG
    Urology; 2007 Dec; 70(6):1091-5. PubMed ID: 18158024
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
    Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
    J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy.
    Sonpavde G; Khan MM; Svatek RS; Lee R; Novara G; Tilki D; Lerner SP; Amiel GE; Skinner E; Karakiewicz PI; Bastian PJ; Kassouf W; Fritsche HM; Izawa JI; Ficarra V; Dinney CP; Lotan Y; Fradet Y; Shariat SF
    BJU Int; 2011 Sep; 108(5):687-92. PubMed ID: 21087453
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The impact of primary stage on survival in patients with lymph node positive bladder cancer.
    Vieweg J; Gschwend JE; Herr HW; Fair WR
    J Urol; 1999 Jan; 161(1):72-6. PubMed ID: 10037372
    [TBL] [Abstract][Full Text] [Related]  

  • 47. International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy.
    Shariat SF; Svatek RS; Tilki D; Skinner E; Karakiewicz PI; Capitanio U; Bastian PJ; Volkmer BG; Kassouf W; Novara G; Fritsche HM; Izawa JI; Ficarra V; Lerner SP; Sagalowsky AI; Schoenberg MP; Kamat AM; Dinney CP; Lotan Y; Marberger MJ; Fradet Y
    BJU Int; 2010 May; 105(10):1402-12. PubMed ID: 20132195
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Prognostic value of lymph node dissections in bladder cancer treated with radical cystectomy].
    Braud G; Battisti S; Karam G; Bouchot O; Rigaud J
    Prog Urol; 2008 Jun; 18(6):351-7. PubMed ID: 18558323
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lymphadenectomy in bladder cancer: a review.
    Buscarini M; Josephson DY; Stein JP
    Urol Int; 2007; 79(3):191-9. PubMed ID: 17940349
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Partial cystectomy: a contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selection.
    Holzbeierlein JM; Lopez-Corona E; Bochner BH; Herr HW; Donat SM; Russo P; Dalbagni G; Sogani PC
    J Urol; 2004 Sep; 172(3):878-81. PubMed ID: 15310988
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder.
    Karakiewicz PI; Shariat SF; Palapattu GS; Gilad AE; Lotan Y; Rogers CG; Vazina A; Gupta A; Bastian PJ; Perrotte P; Sagalowsky AI; Schoenberg M; Lerner SP
    J Urol; 2006 Oct; 176(4 Pt 1):1354-61; discussion 1361-2. PubMed ID: 16952631
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pelvic lymph node dissection can be curative in patients with node positive bladder cancer.
    Vieweg J; Gschwend JE; Herr HW; Fair WR
    J Urol; 1999 Feb; 161(2):449-54. PubMed ID: 9915424
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [New markers for pharmacological targeting in bladder cancer with lymph node metastasis].
    Herrmann E; Eltze E; Köpke T; Bolenz C; Bierer S; Neumann J; Hertle L; Wülfing C
    Aktuelle Urol; 2007 Sep; 38(5):392-7. PubMed ID: 17907066
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic significance of vascular invasion in patients with bladder cancer who underwent radical cystectomy.
    Harada K; Sakai I; Hara I; Eto H; Miyake H
    Int J Urol; 2005 Mar; 12(3):250-5. PubMed ID: 15828951
    [TBL] [Abstract][Full Text] [Related]  

  • 55. External validation of extranodal extension and lymph node density as predictors of survival in node-positive bladder cancer after radical cystectomy.
    Masson-Lecomte A; Vordos D; Hoznek A; Yiou R; Allory Y; Abbou CC; de la Taille A; Salomon L
    Ann Surg Oncol; 2013 Apr; 20(4):1389-94. PubMed ID: 23208127
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Risk factors for recurrence following radical cystectomy for pathologic node negative bladder cancer.
    Hugen CM; Polcari AJ; Fitzgerald MP; Dauw C; Flanigan RC; Quek ML
    J Surg Oncol; 2010 Sep; 102(4):334-7. PubMed ID: 20607757
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term outcome of radiation-based conservation therapy for invasive bladder cancer.
    Chung PW; Bristow RG; Milosevic MF; Yi QL; Jewett MA; Warde PR; Catton CN; McLean M; Moore M; Tannock IF; Gospodarowicz MK
    Urol Oncol; 2007; 25(4):303-9. PubMed ID: 17628296
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Risk factors and clinical outcomes of patients with node-positive muscle-invasive bladder cancer.
    Bruins HM; Stein JP
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1091-101. PubMed ID: 18588454
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin for histologically proven lymph node positive bladder cancer.
    Nieuwenhuijzen JA; Bex A; Meinhardt W; Kerst JM; Schornagel JH; VAN Tinteren H; Horenblas S
    J Urol; 2005 Jul; 174(1):80-5. PubMed ID: 15947583
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience.
    Kassouf W; Swanson D; Kamat AM; Leibovici D; Siefker-Radtke A; Munsell MF; Grossman HB; Dinney CP
    J Urol; 2006 Jun; 175(6):2058-62. PubMed ID: 16697803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.